Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 molnupiravir studies
Outcomes in molnupiravir studies. Potential risks of the mechanism of action include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity. There is substantial positive publication bias. Two trials (CTRI/2021/05/033864 and CTRI/2021/08/0354242) have reported no significant efficacy, however the results have not been published.
0 0.5 1 1.5+ All studies 32% 11 14,747 Improvement, Studies, Patients Relative Risk Mortality 46% 4 12,413 Ventilation 69% 1 10,512 Hospitalization 2% 5 12,675 Recovery 15% 5 906 Viral clearance 41% 5 12,370 RCTs 36% 9 4,235 RCT mortality 50% 3 1,901 Peer-reviewed 39% 5 3,678 Early 44% 7 3,944 Late 16% 4 10,803 Molnupiravir for COVID-19 c19mp.com Jul 2022 Favorsmolnupiravir Favorscontrol
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION HOSPITALIZATION RECOVERY VIRAL CLEARANCE RCTS RCT MORTALITY PEER-REVIEWED All Early Late Molnupiravir for COVID-19 C19MP.COM JUL 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Tau​2 = 0.36, I​2 = 78.7%, p = 0.048 Early treatment 44% 0.56 [0.31-1.00] 61/2,017 142/1,927 44% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Wong (PSM) 45% 0.55 [0.47-0.63] death 2,116 (n) 8,396 (n) Tau​2 = 0.18, I​2 = 64.9%, p = 0.55 Late treatment 16% 0.84 [0.49-1.45] 11/2,332 1/8,471 16% improvement All studies 32% 0.68 [0.48-0.95] 72/4,349 143/10,398 32% improvement 11 molnupiravir COVID-19 studies c19mp.com Jul 2022 Tau​2 = 0.16, I​2 = 73.4%, p = 0.025 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Tau​2 = 0.00, I​2 = 0.0%, p = 0.024 Early treatment 86% 0.14 [0.02-0.78] 1/849 10/761 86% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control Wong (PSM) 45% 0.55 [0.47-0.63] 2,116 (n) 8,396 (n) Tau​2 = 1.34, I​2 = 71.3%, p = 0.92 Late treatment -10% 1.10 [0.18-6.80] 11/2,332 1/8,471 -10% improvement All studies 46% 0.54 [0.17-1.74] 12/3,181 11/9,232 46% improvement 4 molnupiravir COVID-19 mortality results c19mp.com Jul 2022 Tau​2 = 0.71, I​2 = 51.0%, p = 0.31 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 69% 0.31 [0.16-0.61] 2,116 (n) 8,396 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.00064 Late treatment 69% 0.31 [0.16-0.61] 0/2,116 0/8,396 69% improvement All studies 69% 0.31 [0.16-0.61] 0/2,116 0/8,396 69% improvement 1 molnupiravir COVID-19 mechanical ventilation result c19mp.com Jul 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.00064 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Yip (PSW) -17% 1.17 [0.99-1.39] hosp. Tau​2 = 0.45, I​2 = 76.0%, p = 0.34 Early treatment 33% 0.67 [0.30-1.51] 17/1,121 37/1,042 33% improvement Wong (PSM) 0% 1.00 [0.95-1.04] hosp. time 2,116 (n) 8,396 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.86 Late treatment 0% 1.00 [0.95-1.04] 0/2,116 0/8,396 0% improvement All studies 2% 0.98 [0.79-1.20] 17/3,237 37/9,438 2% improvement 5 molnupiravir COVID-19 hospitalization results c19mp.com Jul 2022 Tau​2 = 0.02, I​2 = 77.3%, p = 0.82 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Tau​2 = 0.53, I​2 = 71.9%, p = 0.079 Early treatment 53% 0.47 [0.20-1.09] 15/1,830 46/1,741 53% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Wong (PSM) 45% 0.55 [0.47-0.63] death 2,116 (n) 8,396 (n) Tau​2 = 1.34, I​2 = 71.3%, p = 0.92 Late treatment -10% 1.10 [0.18-6.80] 11/2,332 1/8,471 -10% improvement All studies 40% 0.60 [0.36-1.00] 26/4,162 47/10,212 40% improvement 7 molnupiravir COVID-19 serious outcomes c19mp.com Jul 2022 Tau​2 = 0.23, I​2 = 76.4%, p = 0.049 Effect extraction pre-specified(most serious outcome) Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Tau​2 = 0.13, I​2 = 54.4%, p = 0.53 Early treatment 18% 0.82 [0.44-1.52] 8/383 3/376 18% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.97 Late treatment 1% 0.99 [0.74-1.34] 0/72 0/75 1% improvement All studies 15% 0.85 [0.66-1.11] 8/455 3/451 15% improvement 5 molnupiravir COVID-19 recovery results c19mp.com Jul 2022 Tau​2 = 0.03, I​2 = 35.2%, p = 0.24 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Improvement, RR [CI] Treatment Control Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Tippabhotla (RCT) 59% 0.41 [0.29-0.57] viral+ 42/610 103/610 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Early treatment 58% 0.42 [0.34-0.53] 90/903 205/844 58% improvement Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 Improvement, RR [CI] Treatment Control Wong (PSM) 17% 0.83 [0.73-0.93] viral+ 2,115 (n) 8,396 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.0021 Late treatment 17% 0.83 [0.74-0.94] 26/2,167 34/8,456 17% improvement All studies 41% 0.59 [0.41-0.86] 116/3,070 239/9,300 41% improvement 5 molnupiravir COVID-19 viral clearance results c19mp.com Jul 2022 Tau​2 = 0.14, I​2 = 86.0%, p = 0.0057 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Tau​2 = 0.14, I​2 = 43.2%, p = 0.0027 Early treatment 53% 0.47 [0.29-0.77] 61/2,017 142/1,927 53% improvement 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Tau​2 = 0.00, I​2 = 0.0%, p = 0.77 Late treatment -8% 1.08 [0.67-1.73] 11/216 1/75 -8% improvement All studies 36% 0.64 [0.40-1.03] 72/2,233 143/2,002 36% improvement 9 molnupiravir COVID-19 Randomized Controlled Trials c19mp.com Jul 2022 Tau​2 = 0.26, I​2 = 60.7%, p = 0.066 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] 0/140 1/62 Improvement, RR [CI] Treatment Control Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] 1/709 9/699 Tau​2 = 0.00, I​2 = 0.0%, p = 0.024 Early treatment 86% 0.14 [0.02-0.78] 1/849 10/761 86% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] 11/216 1/75 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Late treatment -282% 3.82 [0.50-29.1] 11/216 1/75 -282% improvement All studies 50% 0.50 [0.05-5.45] 12/1,065 11/836 50% improvement 3 molnupiravir COVID-19 RCT mortality results c19mp.com Jul 2022 Tau​2 = 2.97, I​2 = 67.3%, p = 0.58 Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Improvement, RR [CI] Treatment Control Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Tau​2 = 0.46, I​2 = 62.7%, p = 0.098 Early treatment 52% 0.48 [0.21-1.14] 23/1,702 48/1,685 52% improvement Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.2 Late treatment -282% 3.82 [0.50-29.1] 11/216 1/75 -282% improvement All studies 39% 0.61 [0.25-1.49] 34/1,918 49/1,760 39% improvement 5 molnupiravir COVID-19 peer reviewed trials c19mp.com Jul 2022 Tau​2 = 0.61, I​2 = 65.2%, p = 0.28 Effect extraction pre-specified(most serious outcome) Favors molnupiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Fischer (RCT) 77% 0.23 [0.01-5.69] death 0/140 1/62 Improvement, RR [CI] Treatment Control Fischer (RCT) 65% 0.35 [0.01-8.33] death 0/55 1/62 Fischer (RCT) 67% 0.33 [0.01-8.03] death 0/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] death 0/23 1/62 Fischer (RCT) -33% 1.33 [0.14-12.5] hosp. 3/140 1/62 Fischer (RCT) -13% 1.13 [0.07-17.6] hosp. 1/55 1/62 Fischer (RCT) -100% 2.00 [0.19-21.5] hosp. 2/62 1/62 Fischer (RCT) 58% 0.42 [0.02-10.0] hosp. 0/23 1/62 Fischer (RCT) 49% 0.51 [0.22-1.18] viral+ 10/118 9/54 Fischer (RCT) 89% 0.11 [0.01-0.86] viral+ 1/53 9/54 Fischer (RCT) 30% 0.70 [0.25-1.93] viral+ 5/43 9/54 Fischer (RCT) -9% 1.09 [0.37-3.18] viral+ 4/22 9/54 Fischer (RCT) 92% 0.08 [0.01-0.62] viral+ 1/117 6/54 Fischer (RCT) 92% 0.08 [0.00-1.34] viral+ 0/53 6/54 Fischer (RCT) 91% 0.09 [0.00-1.48] viral+ 0/42 6/54 Fischer (RCT) 59% 0.41 [0.05-3.20] viral+ 1/22 6/54 Fischer (RCT) 30% 0.70 [0.37-1.36] viral+ 19/137 12/61 Fischer (RCT) 62% 0.38 [0.13-1.12] viral+ 4/53 12/61 Fischer (RCT) -8% 1.08 [0.54-2.18] viral+ 13/61 12/61 Fischer (RCT) 56% 0.44 [0.11-1.83] viral+ 2/23 12/61 Hetero (RCT) 70% 0.30 [0.13-0.70] hosp. 7/371 23/370 Hetero (RCT) 33% 0.67 [0.54-0.82] recov. time 371 (n) 370 (n) Optimus (RCT) 58% 0.42 [0.31-0.58] viral+ 38/175 93/180 Khoo (RCT) -33% 1.33 [0.55-3.26] no recov. 8/12 3/6 Khoo (RCT) -100% 2.00 [0.28-14.2] no recov. 4/12 1/6 Khoo (RCT) -100% 2.00 [0.90-4.43] no recov. 4/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) 0% 1.00 [0.28-3.54] no recov. 2/4 3/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 Khoo (RCT) -200% 3.00 [0.39-23.1] no recov. 2/4 1/6 Khoo (RCT) -50% 1.50 [0.13-17.7] no recov. 1/4 1/6 Jayk Bernal (RCT) 89% 0.11 [0.01-0.86] death 1/709 9/699 Jayk Bernal (RCT) 30% 0.70 [0.49-0.99] death/hosp. 48/709 68/699 Jayk Bernal (RCT) 94% 0.06 [0.00-0.97] death/hosp. 0/37 9/47 Jayk Bernal (RCT) 50% 0.50 [0.20-1.26] death/hosp. 6/75 13/82 Jayk Bernal (RCT) 24% 0.76 [0.42-1.38] death/hosp. 18/237 22/221 Jayk Bernal (RCT) 42% 0.58 [0.20-1.68] death/hosp. 5/47 7/38 Tippabhotla (RCT) 46% 0.54 [0.22-1.34] hosp. 7/610 13/610 Tippabhotla (RCT) 46% 0.54 [0.41-0.71] no improv. 67/610 125/610 Tippabhotla (RCT) 52% 0.48 [0.42-0.54] no improv. 199/610 417/610 Tippabhotla (RCT) 25% 0.75 [0.71-0.79] no improv. 433/610 576/610 Tippabhotla (RCT) 59% 0.41 [0.29-0.57] viral+ 42/610 103/610 Tippabhotla (RCT) 81% 0.19 [0.15-0.24] viral+ 62/610 327/610 Tippabhotla (RCT) 78% 0.22 [0.19-0.27] viral+ 113/610 505/610 Yip (PSW) -12% 1.12 [0.68-1.82] death/ICU Yip (PSW) -17% 1.17 [0.99-1.39] hosp. 033864 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 035424 (RCT) 0% 1.00 [0.50-2.00] improv. n/a n/a FUTILITY, PENDING​1 Arribas (DB RCT) -282% 3.82 [0.50-29.1] death 11/216 1/75 Arribas (DB RCT) -217% 3.17 [0.34-29.8] death 3/71 1/75 Arribas (DB RCT) -317% 4.17 [0.48-36.4] death 4/72 1/75 Arribas (DB RCT) -311% 4.11 [0.47-35.9] death 4/73 1/75 Arribas (DB RCT) 1% 0.99 [0.68-1.45] no recov. 72 (n) 75 (n) Arribas (DB RCT) 12% 0.88 [0.61-1.28] no recov. 73 (n) 75 (n) Arribas (DB RCT) -1% 1.01 [0.69-1.47] no recov. 73 (n) 75 (n) Arribas (DB RCT) 12% 0.88 [0.62-1.25] viral+ 26/52 34/60 Arribas (DB RCT) -2% 1.02 [0.74-1.41] viral+ 29/50 34/60 Arribas (DB RCT) 21% 0.79 [0.56-1.13] viral+ 27/60 34/60 Arribas (DB RCT) 8% 0.92 [0.41-2.08] viral+ 9/53 10/54 Arribas (DB RCT) -48% 1.48 [0.72-3.03] viral+ 14/51 10/54 Arribas (DB RCT) 21% 0.79 [0.34-1.84] viral+ 8/55 10/54 Wong (PSM) 45% 0.55 [0.47-0.63] death 2,116 (n) 8,396 (n) Wong (PSM) 69% 0.31 [0.16-0.61] ventilation 2,116 (n) 8,396 (n) Wong (PSM) 47% 0.53 [0.46-0.62] death/ICU 2,116 (n) 8,396 (n) Wong (PSM) 0% 1.00 [0.95-1.04] hosp. time 2,116 (n) 8,396 (n) Wong (PSM) 17% 0.83 [0.73-0.93] viral+ 2,115 (n) 8,396 (n) molnupiravir COVID-19 outcomes c19mp.com Jul 2022 1 FUTILITY: terminated for futility, results pending Favors molnupiravir Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit